Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Neovasc%2C+an+OPKO+Investee+OPK%29%2C+Receives+FDA+Conditional+Approval+to+Initiate+TIARA-I+Trial+in+U.S/9899916.html for the full story.
OPKO Health, Inc. (NYSE:OPK), reported that its licensee, TESARO, Inc.
(Nasdaq:TSRO), has submitted a New Drug Application (NDA) to the U.S.
Food and Drug Administration (FDA) for approval of oral rolapitant, an
OPKO Health, Inc. (NYSE:OPK)
Q2 2014 Earnings Conference Call
August 12, 2014 8:30 am ET
Steven D. Rubin - EVP, Administration
Phillip Frost - Chairman and CEO
Charles W. Bishop - CEO of OPKO Renal Division
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Opko Health Inc (OPK):